Refractory somatotroph adenomas.
Acromegaly
Aggressive adenomas
Pasireotide
Pegvisomant
Somatostatin receptor ligands
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
03
05
2023
medline:
12
7
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Somatotroph adenomas are usually controlled with standard therapy, which can include surgery, medical treatment and radiotherapy. Some tumors have a more aggressive behavior and are refractory to standard therapy. In this review, we summarize the phenotype of these tumors and the current options for their management.
Identifiants
pubmed: 37316636
doi: 10.1007/s11102-023-01324-5
pii: 10.1007/s11102-023-01324-5
doi:
Substances chimiques
Somatostatin
51110-01-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-268Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, Endocrinology E, S.o (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1–G24
doi: 10.1530/EJE-17-0796
pubmed: 29046323
Liu X, Dai C, Feng M, Li M, Chen G, Wang R (2021) Diagnosis and treatment of refractory pituitary adenomas: a narrative review. Gland Surg 10:1499–1507
doi: 10.21037/gs-20-873
pubmed: 33968701
pmcid: 8102214
Conficoni A, Feraco P, Mazzatenta D, Zoli M, Asioli S, Zenesini C, Fabbri VP, Cellerini M, Bacci A (2020) Biomarkers of pituitary macroadenomas aggressive behaviour: a conventional MRI and DWI 3T study. Br J Radiol 93:20200321
doi: 10.1259/bjr.20200321
pubmed: 32628097
pmcid: 7465851
Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, Camacho AHS, Chimelli L, Niemeyer P, Gadelha MR, Kasuki L (2018) Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 60:415–422
doi: 10.1007/s12020-018-1590-8
pubmed: 29626274
Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238–246
doi: 10.1016/j.tem.2012.11.007
pubmed: 23270713
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen MC, Melmed S (2020) : Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 21, 667–678
Wildemberg LE, Gadelha MR (2016) Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother 17:579–588
doi: 10.1517/14656566.2016.1146688
pubmed: 26808354
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The Lancet Diabetes & Endocrinology 2:875–884
doi: 10.1016/S2213-8587(14)70169-X
Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J, Jonsson P, Hey-Hadavi JH (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179:419–427
doi: 10.1530/EJE-18-0616
pubmed: 30325178
Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schofl C, Schopohl J, Stieg MR, Tonjes A (2020) participants of the German Acromegaly, R.: Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol 182, 275–284
Singh R, Didwania P, Lehrer EJ, Sheehan D, Sheehan K, Trifiletti DM, Sheehan JP (2020) : Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes. J Neurooncol
Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L, Anile C, Colosimo C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A (2019) Pasireotide and Pegvisomant Combination Treatment in Acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab 104:5478–5482
doi: 10.1210/jc.2019-00825
pubmed: 31219586
Luo M, Tan Y, Chen W, Hu B, Wang Z, Zhu D, Jiao H, Duan C, Zhu Y, Wang H (2021) Clinical efficacy of Temozolomide and its predictors in aggressive pituitary tumors and Pituitary Carcinomas: a systematic review and Meta-analysis. Front Neurol 12:700007
doi: 10.3389/fneur.2021.700007
pubmed: 34220696
pmcid: 8250148
Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S (2022) Temozolomide and Capecitabine Treatment for an aggressive Somatotroph Pituitary Tumor: a Case Report and Literature Review. Front Oncol 12:916982
doi: 10.3389/fonc.2022.916982
pubmed: 35712496
pmcid: 9197190
Nakano-Tateno T, Lau KJ, Wang J, McMahon C, Kawakami Y, Tateno T, Araki T (2021) Multimodal Non-Surgical treatments of aggressive pituitary tumors. Front Endocrinol 12:624686
doi: 10.3389/fendo.2021.624686